These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7193277)

  • 21. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum.
    Sako K; Razack MS; Kalnins I
    Am J Surg; 1978 Oct; 136(4):529-33. PubMed ID: 707737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer.
    Osoba D; Band PR; Goldie JH; Connors JM; Gelmon K; Knowling MA; Fetherstonhaugh EM
    Ann Oncol; 1992 Aug; 3 Suppl 3():57-62. PubMed ID: 1390318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Perry DJ; Weltz MD; Brown AW; Henderson RL; Neglia WJ; Berenberg JL
    Cancer; 1982 Dec; 50(11):2257-60. PubMed ID: 6182971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
    Vokes EE; Choi KE; Schilsky RL; Moran WJ; Guarnieri CM; Weichselbaum RR; Panje WR
    J Clin Oncol; 1988 Apr; 6(4):618-26. PubMed ID: 3258629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer.
    Glicksman AS; Slotman G; Doolittle C; Clark J; Koness J; Coachman N; Posner M; DeRosa E; Wanebo H
    Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1043-50. PubMed ID: 7961010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.
    Osoba D; Band PR; Connors JM; Goldie JH; Knowling MA; Fetherstonhaugh EM
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):25-9; discussion 30-1. PubMed ID: 1384140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin and mitoguazone. An induction chemotherapy regimen in advanced head and neck cancer.
    Forastiere AA; Perry DJ; Wolf GT; Wheeler RH; Natale RB
    Cancer; 1988 Dec; 62(11):2304-8. PubMed ID: 3179946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
    Airoldi M; Pedani F; Brando V; Giordano C; Gabriele P
    Chemioterapia; 1988 Apr; 7(2):127-9. PubMed ID: 3396116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
    Merlano M; Tatarek R; Grimaldi A; Margarino G; Rosso R
    Cancer Treat Rep; 1985 Sep; 69(9):961-4. PubMed ID: 4040809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
    J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 24-hour infusion of cis-platinum in head and neck cancers.
    Jacobs C; Bertino JR; Goffinet DR; Fee WE; Goode RL
    Cancer; 1978 Nov; 42(5):2135-40. PubMed ID: 719601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck.
    Brown AW; Blom J; Butler WM; Garcia-Guerrero G; Richardson MF; Henderson RL
    Cancer; 1980 Jun; 45(11):2830-5. PubMed ID: 6155199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
    Kish JA; Ensley JF; Jacobs JR; Binns P; al-Sarraf M
    Am J Clin Oncol; 1988 Oct; 11(5):553-7. PubMed ID: 3177258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.